256 related articles for article (PubMed ID: 21889582)
1. Nanosuspensions as advanced printing ink for accurate dosing of poorly soluble drugs in personalized medicines.
Pardeike J; Strohmeier DM; Schrödl N; Voura C; Gruber M; Khinast JG; Zimmer A
Int J Pharm; 2011 Nov; 420(1):93-100. PubMed ID: 21889582
[TBL] [Abstract][Full Text] [Related]
2. Preparation of a chemically stable quercetin formulation using nanosuspension technology.
Gao L; Liu G; Wang X; Liu F; Xu Y; Ma J
Int J Pharm; 2011 Feb; 404(1-2):231-7. PubMed ID: 21093559
[TBL] [Abstract][Full Text] [Related]
3. Development of novel polymer-stabilized diosmin nanosuspensions: in vitro appraisal and ex vivo permeation.
Freag MS; Elnaggar YS; Abdallah OY
Int J Pharm; 2013 Sep; 454(1):462-71. PubMed ID: 23830765
[TBL] [Abstract][Full Text] [Related]
4. Nanosuspensions: a promising formulation for the new phospholipase A2 inhibitor PX-18.
Pardeike J; Müller RH
Int J Pharm; 2010 May; 391(1-2):322-9. PubMed ID: 20214969
[TBL] [Abstract][Full Text] [Related]
5. Development of ascorbyl palmitate nanocrystals applying the nanosuspension technology.
Teeranachaideekul V; Junyaprasert VB; Souto EB; Müller RH
Int J Pharm; 2008 Apr; 354(1-2):227-34. PubMed ID: 18242898
[TBL] [Abstract][Full Text] [Related]
6. Lutein nanocrystals as antioxidant formulation for oral and dermal delivery.
Mitri K; Shegokar R; Gohla S; Anselmi C; Müller RH
Int J Pharm; 2011 Nov; 420(1):141-6. PubMed ID: 21884768
[TBL] [Abstract][Full Text] [Related]
7. Combining inkjet printing and amorphous nanonization to prepare personalized dosage forms of poorly-soluble drugs.
Cheow WS; Kiew TY; Hadinoto K
Eur J Pharm Biopharm; 2015 Oct; 96():314-21. PubMed ID: 26325060
[TBL] [Abstract][Full Text] [Related]
8. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs.
Kassem MA; Abdel Rahman AA; Ghorab MM; Ahmed MB; Khalil RM
Int J Pharm; 2007 Aug; 340(1-2):126-33. PubMed ID: 17600645
[TBL] [Abstract][Full Text] [Related]
9. Formulation, evaluation and optimization of the felodipine nanosuspension to be used for direct compression to tablet for in vitro dissolution enhancement.
Mori D; Makwana J; Parmar R; Patel K; Chavda J
Pak J Pharm Sci; 2016 Nov; 29(6):1927-1936. PubMed ID: 28375107
[TBL] [Abstract][Full Text] [Related]
10. Continuous and scalable process for water-redispersible nanoformulation of poorly aqueous soluble APIs by antisolvent precipitation and spray-drying.
Hu J; Ng WK; Dong Y; Shen S; Tan RB
Int J Pharm; 2011 Feb; 404(1-2):198-204. PubMed ID: 21056643
[TBL] [Abstract][Full Text] [Related]
11. Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions.
Gao L; Zhang D; Chen M; Duan C; Dai W; Jia L; Zhao W
Int J Pharm; 2008 May; 355(1-2):321-7. PubMed ID: 18242896
[TBL] [Abstract][Full Text] [Related]
12. Comparison of different methods for preparation of a stable riccardin D formulation via nano-technology.
Liu G; Zhang D; Jiao Y; Zheng D; Liu Y; Duan C; Jia L; Zhang Q; Lou H
Int J Pharm; 2012 Jan; 422(1-2):516-22. PubMed ID: 22119965
[TBL] [Abstract][Full Text] [Related]
13. Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs.
Kocbek P; Baumgartner S; Kristl J
Int J Pharm; 2006 Apr; 312(1-2):179-86. PubMed ID: 16469459
[TBL] [Abstract][Full Text] [Related]
14. Application of the combinative particle size reduction technology H 42 to produce fast dissolving glibenclamide tablets.
Salazar J; Müller RH; Möschwitzer JP
Eur J Pharm Sci; 2013 Jul; 49(4):565-77. PubMed ID: 23587645
[TBL] [Abstract][Full Text] [Related]
15. Development of PIK-75 nanosuspension formulation with enhanced delivery efficiency and cytotoxicity for targeted anti-cancer therapy.
Talekar M; Ganta S; Amiji M; Jamieson S; Kendall J; Denny WA; Garg S
Int J Pharm; 2013 Jun; 450(1-2):278-89. PubMed ID: 23632263
[TBL] [Abstract][Full Text] [Related]
16. Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base.
Hecq J; Deleers M; Fanara D; Vranckx H; Boulanger P; Le Lamer S; Amighi K
Eur J Pharm Biopharm; 2006 Nov; 64(3):360-8. PubMed ID: 16846725
[TBL] [Abstract][Full Text] [Related]
17. A comparative study of top-down and bottom-up approaches for the preparation of micro/nanosuspensions.
Verma S; Gokhale R; Burgess DJ
Int J Pharm; 2009 Oct; 380(1-2):216-22. PubMed ID: 19596059
[TBL] [Abstract][Full Text] [Related]
18. Effect of process parameters on nanoemulsion droplet size and distribution in SPG membrane emulsification.
Oh DH; Balakrishnan P; Oh YK; Kim DD; Yong CS; Choi HG
Int J Pharm; 2011 Feb; 404(1-2):191-7. PubMed ID: 21055456
[TBL] [Abstract][Full Text] [Related]
19. Enhance the dissolution rate and oral bioavailability of pranlukast by preparing nanosuspensions with high-pressure homogenizing method.
Wang L; Hao Y; Liu N; Ma M; Yin Z; Zhang X
Drug Dev Ind Pharm; 2012 Nov; 38(11):1381-9. PubMed ID: 22300415
[TBL] [Abstract][Full Text] [Related]
20. Is the amorphous fraction of a dried nanosuspension caused by milling or by drying? A case study with Naproxen and Cinnarizine.
Kayaert P; Van den Mooter G
Eur J Pharm Biopharm; 2012 Aug; 81(3):650-6. PubMed ID: 22579733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
